Patritumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePatritumab
Drug Alias Name帕曲妥单抗patritumabum64Cu-DOTA-U3-1287帕曲妥人单抗AMG-888 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[20] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen IncDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWashington University School Of MedicineU3 Pharma GmbhDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksWikipedia